Old Web
English
Sign In
Acemap
>
authorDetail
>
Laurence Hatteville
Laurence Hatteville
RAND Corporation
Refractory
Medicine
Rituximab
Maytansinoid
Lymphoma
3
Papers
138
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
2016
British Journal of Haematology
Bertrand Coiffier
Catherine Thieblemont
Sophie de Guibert
Jehan Dupuis
Vincent Ribrag
Reda Bouabdallah
Franck Morschhauser
Robert Navarro
Steven Le Gouill
Corinne Haioun
Roch Houot
Olivier Casasnovas
Harald Holte
Thierry Lamy
Florence Broussais
Sandrine Payrard
Laurence Hatteville
Hervé Tilly
Show All
Source
Cite
Save
Citations (36)
A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
2014
Clinical Cancer Research
Vincent Ribrag
Jehan Dupuis
Hervé Tilly
Franck Morschhauser
Fabrice Laine
Roch Houot
Corinne Haioun
Christiane Copie
Andrea Varga
John M. Lambert
Laurence Hatteville
Samira Ziti-Ljajic
Anne Caron
Sandrine Payrard
Bertrand Coiffier
Show All
Source
Cite
Save
Citations (87)
Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887)
2014
Journal of Clinical Oncology
Marek Trneny
Gregor Verhoef
Martin J. S. Dyer
Dina Ben Yehuda
Caterina Patti
Miguel Canales
Andres Lopez
Farrukh T. Awan
Paul Montgomery
Andrea Janíková
Anna Maria Barbui
Kazimierz Sulek
María José Terol
John Radford
Laure Siraudin
Laurence Hatteville
Sandrine Schwab
Corina Oprea
Alessandro M. Gianni
Show All
Source
Cite
Save
Citations (15)
1